Reykjavik, Iceland & Dubai, United Arab Emirates — Alvotech (NASDAQ: ALVO) and Bioventure, a wholly owned subsidiary of GlobalOne Healthcare Holding LLC, today announced that the Egyptian Drug Authority (EDA) has approved the manufacturing and distribution of AVT02 (adalimumab) a biosimilar for Humira®, which is commonly indicated for the treatment of rheumatoid arthritis and several...
Alvotech and Bioventure announce approval of AVT02 – adalimumab – in Egypt
